Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | GALK1 | P51570 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046506 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL4318187 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL3046511 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL6873291 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL8727122 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL6367492 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5032458 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5032455 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL7143078 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL6865171 | 1.00 | SLC6A2 (0.58) | SLC6A2SYNJ2KDM4EABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800742-B2 | Method for producing β-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2004-10-05 | — | — | US | claimed |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2002-12-12 | — | — | US | claimed |
| EP-1260516-A1 | Method for producing a beta-D-ribofuranose derivative or an optical isomer thereof | Ajinomoto Co., Inc. (JP) | 2002-11-27 | — | — | EP | claimed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| US-6800742-B2 | Method for producing β-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-6800742-B2 | Method for producing β-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1260516-A1 | Method for producing a beta-D-ribofuranose derivative or an optical isomer thereof | Ajinomoto Co., Inc. (JP) | 2002-11-27 | — | — | EP | disclosed |
| EP-1260516-A1 | Method for producing a beta-D-ribofuranose derivative or an optical isomer thereof | Ajinomoto Co., Inc. (JP) | 2002-11-27 | — | — | EP | disclosed |
| EP-0320942-A2 | Novel polysaccharides novel macromolecular conjugates of the polysaccharides | AMERICAN CYANAMID COMPANY (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | SLC6A2 2320/4885SYNJ2 259/4885KDM4E 4719/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | SLC6A2 2426/4885SYNJ2 1685/4885KDM4E 4217/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | SLC6A2 2320/4885SYNJ2 259/4885KDM4E 4719/4885 |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | DERA, RNGTT, DUT | SLC6A2 3722/4885SYNJ2 4702/4885KDM4E 3095/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | SLC6A2 3113/4885SYNJ2 2189/4885KDM4E 2965/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | SLC6A2 4676/4885SYNJ2 2624/4885KDM4E 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.